← back to search

Jie Huang

North China Electric Power University · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, MicroRNA in disease regulation, and HER2/EGFR in Cancer Research.
h-index
26
citations
2,187
works
106
NIH funding
primary concept
Medicine
email

Recent publications

First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
Journal of Thoracic Oncology 2025cited by 13position: middledoi
Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma
Nature Communications 2024cited by 27position: middledoi
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
Nature Medicine 2023cited by 60position: middledoi
Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes
Nature Communications 2023cited by 24position: middledoi
The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
Cancer Medicine 2023cited by 3position: middledoi
Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies
Nature Communications 2022cited by 79position: middledoi
Application of a Fluorescent H <sub>2</sub> S Probe Based on Excited-State Intramolecular Proton Transfer for Detecting Latent Mechanism of H <sub>2</sub> S-induced MCF-7 Apoptosis
Future Medicinal Chemistry 2022cited by 5position: middledoi
QKI is a critical pre-mRNA alternative splicing regulator of cardiac myofibrillogenesis and contractile function
Nature Communications 2021cited by 102position: middledoi
BMAL1 regulates mitochondrial fission and mitophagy through mitochondrial protein BNIP3 and is critical in the development of dilated cardiomyopathy
Protein & Cell 2020cited by 135position: middledoi
miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression
Journal of Cellular and Molecular Medicine 2017cited by 63position: middledoi

Grants

RAPID: A Novel Detector for Mitigating the Covid-19 Pandemic based on Phase Interrogated Ultra-sensitive Microwave Resonance
NSF2027571$200,0002020–2023PIRePORTER

Frequent collaborators

Chen Xu · State University "Kyiv Aviation Institute"3 papers (2022–2024)Chen Ding · Beijing University of Chemical Technology3 papers (2022–2024)Yingyong Hou · Shanghai Medical College of Fudan University3 papers (2022–2024)Qiao Zhang · Fudan University2 papers (2023–2024)Ning Sun · Jiangnan University2 papers (2020–2021)Jian‐Yuan Zhao · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2022–2023)Yunzhi Wang · XinHua Hospital2 papers (2022–2024)Yang Liu · The First People's Hospital of Changde2 papers (2022–2023)Dongxian Jiang · U.S. National Science Foundation2 papers (2022–2023)Jinwen Feng · Shanghai Jiao Tong University2 papers (2022–2023)Xiuya Li · Fudan University2 papers (2020–2021)Subei Tan · Fudan University2 papers (2023–2024)Chen Xu · Fudan University2 papers (2020–2021)Sha Tian · Fudan University2 papers (2022–2023)Zhaoyu Qin · Fudan University2 papers (2022–2023)Zixiang Yu · Fujian Normal University2 papers (2023–2024)Xinyun Chen · Fudan University1 papers (2021–2021)Qianqian Liang · Fudan University1 papers (2020–2020)Maria Sanderson · Indiana University School of Medicine1 papers (2021–2021)Maofang Zhao · Xuzhou Medical College1 papers (2022–2022)